Precision BioLogic Inc., a leader in hemostasis diagnostics, has expanded the utility of its CRYOcheck Chromogenic Factor VIII assay to support emerging hemophilia treatments such as Mim8. First launched in 2020 as the FDA-cleared chromogenic FVIII assay for automated instruments, it now demonstrates accuracy even in the presence of Emicizumab and expected levels of Mim8. Compatible with all major analyzers, the assay ensures efficiency, precision, and ease of use, supporting laboratories worldwide in managing hemophilia A.
